Press Releases

• 05/07/2013
  Mersana to Participate in the UBS Global Healthcare Conference
• 04/09/2013
  Mersana Therapeutics Presents Positive Preclinical Data on Next-Generation Antibody-Drug Conjugate Technology at AACR Annual Meeting
• 03/29/2013
  Mersana to Participate in Four Upcoming Conferences
• 03/11/2013
  Mersana to Participate in the Massachusetts Biotechnology Council Annual Meeting
• 02/20/2013
  Mersana to Participate in Oncology Partnering and Deal Making and ADC Development & Production Conferences
• 02/04/2013
  Mersana to Participate in the BIO CEO & Investor Conference
• 01/23/2013
  Mersana Therapeutics Expands Senior Leadership Team with Appointments of Peter Park, Ph.D., as VP of Biology and Wayne Foster, CPA, as VP of Finance

• 09/19/2012
  Mersana Therapeutics Named a "Fierce 15" Biotech Company for 2012
• 08/01/2012
  Adimab and Mersana Announce Antibody-Drug Conjugate Alliance
• 07/31/2012
  Mersana Therapeutics Raises $27M to Advance Fleximer^® Antibody-drug Conjugates
• 03/07/2012
  Mersana Therapeutics Enters Collaboration with Endo Pharmaceuticals to Develop Next-generation Antibody-drug Conjugates
• 02/27/2012
  Mersana Therapeutics to Participate in Four Upcoming Conferences

• 10/17/2011
  Mersana Therapeutics to Participate in the Annual BIO Investor Forum
• 08/19/2011
  Mersana Therapeutics to Participate in BioPharm America and UBS Global Life Sciences Conferences
• 04/20/2011
  Mersana Therapeutics Appoints Michael A. Metzger as EVP & COO
• 03/25/2011
  Mersana Therapeutics Initiates Phase 1b Extension Study of XMT-1001 in Gastric Cancer and Non-Small Cell Lung Cancer

• 09/29/2010
  Mersana Therapeutics Appoints Nicholas Bacopoulos President and Chief Executive Officer
• 06/23/2010
  Mersana Initiates Phase 1 Clinical Trial for XMT-1107 in Oncology
• 04/20/2010
  Mersana Therapeutics Presents Data Demonstrating XMT-1001 Substantially Accumulates in Tumor and Results in Significantly Prolonged Drug Exposure
• 04/13/2010
  Mersana Enters Research and Exclusive License Agreement with Teva Pharmaceuticals for the Development and Commercialization of XMT-1107

• 11/17/2009
  Mersana Therapeutics Provides Clinical Update from Ongoing Phase 1 Study of XMT-1001 in Patients with Advanced Solid Tumors
• 11/12/2009
  Mersana Therapeutics Publishes Review Article Detailing Advantages of it Lead Cancer Compound in Journal of Advanced Drug Delivery Reviews
• 06/01/2009
  Mersana Reports Preliminary Phase 1 Results of XMT-1001 in Patients with Advanced Solid Tumors
• 04/19/2009
  Mersana's Second Development Candidate, XMT-1107, Shows Superior Pharmacokinetics and Anti-Tumor Activity in Studies Presented at American Association of Cancer Research Meeting

• 04/14/2008
  Mersana's Second Development Candidate, XMT-1107, Shows Superior Pharmacokinetics and Anti-Tumor Activity in Studies Presented at American Association of Cancer Research Meeting
• 02/12/2008
  Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
• 01/03/2008
  Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors

• 10/24/2007
  Mersana Therapeutics Reports Phase I Results for XMT-1001 in Patients with Solid Tumors at AACR-NCI-EORTC International Conference
• 07/12/2007
  Mersana Therapeutics, Inc. Appoints Pharmaceutical Industry Veteran Nicholas G. Bacopoulos, Ph.D. to Board of Directors
• 05/30/2007
  Mersana Therapeutics, Inc. Initiates Phase I Trial of Anti-Cancer Agent, XMT-1001, in Solid Tumors
• 04/13/2007
  Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting

• 11/08/2005
  Mersana Therapeutics, Inc. Completes $21 Million Financing